BioCryst Pharmaceuticals, Inc. BCRX
Regular-session close
Pre-market · Nov 19, 7:33 AM ET
- YTD
- -6.41%
- 1 year
- +4.29%
5D -0.06 (-0.79%)
- Market cap
- 1.88B
- Revenue (ttm)
- 961.51M
- Profit margin
- -37.41%
- EPS (ttm)
- -1.28
- Shares out
- 257.30M
- Forward P/E
- 8.54
- YTD return
- -6.41%
- 1-year return
- +4.29%
- 50-day average
- 8.15
- 200-day average
- 8.81
- Volume
- 2.95M
- Avg volume
- 4.93M
- Open
- 7.50
- Previous close
- 7.50
- Day's range
- 7.28 – 7.64
- 52-week range
- 6.23 – 11.22
- Beta
- 0.51
- Analysts
- Buy
- Price target
- 20.45 (+180.2%)
- Earnings date
- Feb 25, 2027
Key statistics
- Enterprise value
- 2.38B
- PEG ratio
- 9.39
- Price / sales
- 1.95
- Revenue growth
- 13.10%
- Free cash flow
- 301.09M
- Total cash
- 375.00M
- Total debt
- 828.20M
- Short % of float
- 10.82%
Fundamental scorecard
8 of 25 checks passed on BCRX’s reported financials
8of 25 checks passed
- Value 2 of 5
- Growth 3 of 5
- Profitability 1 of 5
- Financial health 2 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 11.00
- Target (mean)
- 20.45
- Target (high)
- 32.00
- Strong buy2
- Buy7
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate 0.10.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | 0.11 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 0.09186 | 0.14 | +0.05 | +52.41% |
| Aug 5, 2026 | Jun 30, 2026 | 0.1542 | 0.30 | +0.15 | +94.55% |
| May 6, 2026 | Mar 31, 2026 | 0.06 | -2.98 | -3.04 | -5,066.67% |
| Feb 26, 2026 | Dec 31, 2025 | 0.07 | 1.12 | +1.05 | +1,500.00% |
| Nov 3, 2025 | Sep 30, 2025 | 0.07 | 0.06 | -0.01 | -14.29% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2026 | Wedbush | main | Outperform | Outperform |
| Sep 30, 2026 | JP Morgan | main | Neutral | Neutral |
| Sep 10, 2026 | RBC Capital | down | Outperform | Sector Perform |
| Sep 8, 2026 | Needham | reit | Buy | Buy |
| Aug 6, 2026 | RBC Capital | main | Outperform | Outperform |
| Aug 6, 2026 | Wedbush | main | Outperform | Outperform |
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- biocryst.com
News
BioCryst Pharma Announces New Real-World Evidence On Use Of Once-Daily ORLADEYO For Patients With Hereditary Angioedema, Showing Reductions In Hospitalizations And Emergency Department Visits
BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting Wedbush Maintains Outperform on BioCryst Pharma, Lowers Price Target to $17
BioCryst Pharma Q3 2026 Earnings Call Transcript BioCryst Pharma Raises FY2026 Sales Guidance from $690.000M-$715.000M to $715.000M-$730.000M vs $710.134M Est
Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade FDA Approves BioCryst Pharma’s sNDA For Use Of Oral Pellet Formulation Of Once-Daily ORLADEYO For Prophylactic Therapy In Adults And Adolescents Aged 12 Years And Older
Your note
Sign in to keep a note on BCRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARNES ALANE P | Officer | Sale | May 12, 2026 | 400,703 |
| DOYLE ANTHONY | Chief Financial Officer | Stock Award(Grant) | Dec 18, 2024 | 377,867 |
| GALSON STEVEN K | Director | Stock Award(Grant) | Jun 10, 2026 | 86,165 |
| GAYER CHARLES K | President | Conversion of Exercise of derivative security | Dec 21, 2025 | 952,583 |
| GHIAS BABAR | Chief Financial Officer | Stock Award(Grant) | Dec 16, 2025 | 268,700 |
| HUTSON NANCY J | Director | Stock Award(Grant) | Jun 11, 2025 | 99,138 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.46% | 24,334,456 | 177.64M | Sep 29, 2026 |
| Deerfield Management Company, L.P | 6.02% | 15,490,928 | 113.08M | Sep 29, 2026 |
| State Street Corporation | 4.78% | 12,294,412 | 89.75M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.38% | 11,266,982 | 82.25M | Sep 29, 2026 |
| TCG Crossover Management, LLC | 4.28% | 11,020,968 | 80.45M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 4.09% | 10,533,324 | 76.89M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.14% | 8,067,362 | 58.89M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.68% | 6,891,002 | 50.30M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.25% | 5,791,336 | 42.28M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.13% | 2,911,465 | 21.25M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.10% | 2,838,097 | 20.72M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.99% | 2,542,173 | 18.56M | Aug 30, 2026 |
